Aryzta AG Earnings Calls
| Release date | Mar 02, 2026 |
| EPS estimate | - |
| EPS actual | $0.280 |
| Revenue estimate | 561.096M |
| Revenue actual | 1.326B |
| Revenue Surprise | 136.24% |
| Release date | Aug 11, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Mar 03, 2025 |
| EPS estimate | - |
| EPS actual | $2.97 |
| Revenue estimate | 529M |
| Revenue actual | 1.18B |
| Revenue Surprise | 123.01% |
| Release date | Oct 21, 2024 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
Last 4 Quarters for Aryzta AG
Below you can see how ARZTY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Oct 21, 2024 |
| Price on release | $0.90 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Oct 15, 2024 | $0.99 |
| Oct 16, 2024 | $0.90 |
| Oct 17, 2024 | $0.90 |
| Oct 18, 2024 | $0.90 |
| Oct 21, 2024 | $0.90 |
| Oct 22, 2024 | $0.90 |
| Oct 23, 2024 | $0.90 |
| Oct 24, 2024 | $0.90 |
| Oct 25, 2024 | $0.90 |
| 4 days before | -9.09% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | -9.09% |
| Release date | Mar 03, 2025 |
| Price on release | $1.14 |
| EPS estimate | - |
| EPS actual | $2.97 |
| Date | Price |
|---|---|
| Feb 25, 2025 | $1.05 |
| Feb 26, 2025 | $1.05 |
| Feb 27, 2025 | $1.05 |
| Feb 28, 2025 | $1.05 |
| Mar 03, 2025 | $1.14 |
| Mar 04, 2025 | $1.14 |
| Mar 05, 2025 | $1.14 |
| Mar 06, 2025 | $1.14 |
| Mar 07, 2025 | $1.14 |
| 4 days before | 8.57% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 8.57% |
| Release date | Aug 11, 2025 |
| Price on release | $8.92 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Aug 06, 2025 | $8.92 |
| Aug 07, 2025 | $8.92 |
| Aug 08, 2025 | $8.92 |
| Aug 09, 2025 | $8.92 |
| Aug 11, 2025 | $8.92 |
| Aug 12, 2025 | $9.49 |
| Aug 13, 2025 | $9.49 |
| Aug 14, 2025 | $9.49 |
| Aug 15, 2025 | $9.49 |
| 4 days before | 0% |
| 4 days after | 6.39% |
| On release day | 6.39% |
| Change in period | 6.39% |
| Release date | Mar 02, 2026 |
| Price on release | $6.48 |
| EPS estimate | - |
| EPS actual | $0.280 |
| Date | Price |
|---|---|
| Feb 24, 2026 | $6.48 |
| Feb 25, 2026 | $6.48 |
| Feb 26, 2026 | $6.48 |
| Feb 27, 2026 | $6.48 |
| Mar 02, 2026 | $6.48 |
| Mar 03, 2026 | $6.48 |
| Mar 04, 2026 | $6.48 |
| Mar 05, 2026 | $6.48 |
| Mar 06, 2026 | $6.48 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
Aryzta AG Earnings Call Transcript Summary of Q4 2025
ARYZTA reported FY2025 revenues of EUR 2.223 billion (organic growth +1.5%), EBITDA of EUR 306.9 million (13.8% margin) and free cash flow of EUR 120 million. The company completed customer negotiations for year-end 2025/beginning 2026, sustained an innovation share of 19% of revenue, and is ramping new capacity in Switzerland and other planned investments in Portugal and Poland. Management confirmed delivery of the midterm plan trajectory: low- to mid-single-digit organic growth, ongoing EBITDA/EBIT margin improvement, disciplined CapEx (3.5–4.5% of revenue), and a target net debt leverage of 1.5–2.0x. ARYZTA will repurchase the remaining hybrid bond principal (CHF 144.3m) by end-April 2026, normalizing the financing structure. Cost and efficiency programs have been consolidated under an “ARYZTA Continuous Excellence” program targeting EUR 20–30m net savings over the midterm (with EUR 40–60m gross operations/procurement/structure savings, part of which will be reinvested in digital/AI). Working capital improvements reduced trade NWC to 0.2% of revenue and helped lower leverage to 2.6x; core equity rose to 21.1% (targeting progress toward ~30%). Management expects continued strong cash generation in 2026, more H2-weighted cash flow due to planned factory and capex timing, pricing largely flat for the year, and ongoing margin recovery with restructuring costs in 2026 and full benefits more visible in 2027. The Board will publish a capital allocation/return policy in 2026.
Sign In
Buy ARZTY